Physician profile
Elving Colon
NPI 1104051119
$2,039.34
in general payments reported to CMS, 2019-2025
20 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.53 · 2021: $351 · 2022: $445 · 2023: $521 · 2024: $382 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $662.58 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $443.09 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $336.22 | 2021-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $106.81 | 2021-2025 | Viberzi, Linzess |
| Pfizer INC. | $88.91 | 2023-2024 | |
| Astellas Pharma US INC | $44.96 | 2021-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.38 | 2022-2025 | Xifaxan |
| Amgen INC. | $39.81 | 2023-2024 | Otezla, Repatha |
| Lilly USA, LLC | $38.21 | 2022-2025 | Kisunla |
| Biohaven Pharmaceutical Holding Company LTD. | $32.99 | 2022 | |
| Almatica Pharma LLC | $29.38 | 2023 | Gralise, Sertraline Hcl, Loreev Xr |
| Hologic Sales and Service, LLC | $27.65 | 2023-2024 | Aptima |
| Novartis Pharmaceuticals Corporation | $23.98 | 2022 | |
| Axsome Therapeutics, INC. | $21.65 | 2025 | Auvelity |
| Linus Health, INC. | $19.75 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $19.43 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.33 | 2024 | Rexulti |
| Corium, LLC | $16.75 | 2021 | |
| Seqirus USA INC | $14.93 | 2022 | |
| Genentech USA, INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elving Colon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.